Rosland McLeod Named Chief Compliance Officer at Biogen Idec Inc.

Rosland McLeod has been named the next VP Chief Compliance Officer at Biogen Idec Inc., in Boston, MA. Ms. McLeod will begin her role of VP Chief Compliance Officer January 12, 2009.

Ms.McLeod will be responsible for:

• Developing, implementing, administering, updating and monitoring the Company’s compliance programs adopted by business units throughout all areas and functions of the Company.
• Ensuring that internal reporting mechanisms are developed, implemented, maintained and actively monitored to enable Company employees to report suggestions or concerns regarding the Company’s compliance programs and potential compliance violations.
• Ensuring that all concerns and reports of violations throughout the Company are investigated and resolved.
• Ensuring that the Finance and Audit Committee is immediately notified of concerns or reports of violations relating to members of senior management, as well as accounting, internal control, auditing, regulatory or financial matters.
• Coordinating with the Internal Audit Department on matters relating to audits and other techniques to monitor compliance and to monitor and address identified risk areas and to ensure that robust auditing and monitoring systems are in place.
• Chairing Committee meetings. This includes scheduling regular and ad hoc meetings, preparing agendas for meetings and, where necessary, distributing materials to Committee members in advance of meetings.

Rosland McLeod was previously a Partner in the Healthcare Practice of K&L Gates, LLP.  Ms. McLeod’s previous professional positions include General Counsel and Ethics & Compliance Officer at Novation, LLC and VP of Legal Operations at Triad Hospitals, Inc.  Ms. McLeod obtained her Juris Doctor from University of Houston Law Center.

Biogen Idec of Boston, MA has $3.2BB in revenue. The biotech giant, formed from the merger of Idec Pharmaceuticals and Biogen, is focused on developing treatments in the areas of oncology, immunology, and neurology. Its product roster includes best-selling Avonex, the most popular drug for the treatment of relapsing multiple sclerosis; Rituxan, a monoclonal antibody developed with Genentech that treats B-cell non-Hodgkin’s lymphoma (NHL); multiple sclerosis drug Tysabri; and Fumaderm, a psoriasis drug marketed in Germany.

Print PDF